Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-1.11%)
USD 0.01
(-1.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -17.84 Million USD | 78.78% |
| 2022 | -84.12 Million USD | 49.57% |
| 2021 | -166.8 Million USD | -60.97% |
| 2020 | -103.62 Million USD | -96.47% |
| 2019 | -52.74 Million USD | 32.07% |
| 2018 | -77.64 Million USD | -672.96% |
| 2017 | -10.04 Million USD | 16.59% |
| 2016 | -12.04 Million USD | 71.36% |
| 2015 | -42.04 Million USD | -338.42% |
| 2014 | -9.59 Million USD | 33.5% |
| 2013 | -14.42 Million USD | -151.22% |
| 2012 | -5.74 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.84 Million USD | 15.86% |
| 2024 Q2 | -1.38 Million USD | 51.16% |
| 2023 Q2 | -7.33 Million USD | -104.97% |
| 2023 Q1 | -3.57 Million USD | 70.3% |
| 2023 FY | -17.84 Million USD | 78.78% |
| 2023 Q4 | -3.38 Million USD | 4.84% |
| 2023 Q3 | -3.55 Million USD | 51.58% |
| 2022 Q1 | -28.92 Million USD | 22.69% |
| 2022 FY | -84.12 Million USD | 49.57% |
| 2022 Q4 | -12.05 Million USD | 35.63% |
| 2022 Q3 | -18.72 Million USD | 23.32% |
| 2022 Q2 | -24.41 Million USD | 15.59% |
| 2021 Q2 | -41.14 Million USD | 8.31% |
| 2021 Q3 | -43.36 Million USD | -5.41% |
| 2021 FY | -166.8 Million USD | -60.97% |
| 2021 Q4 | -37.41 Million USD | 13.72% |
| 2021 Q1 | -44.87 Million USD | -25.16% |
| 2020 Q1 | -19.24 Million USD | -49.5% |
| 2020 Q2 | -22.37 Million USD | -16.25% |
| 2020 Q4 | -35.85 Million USD | -37.07% |
| 2020 Q3 | -26.15 Million USD | -16.91% |
| 2020 FY | -103.62 Million USD | -96.47% |
| 2019 Q1 | -13.63 Million USD | 9.0% |
| 2019 Q4 | -12.87 Million USD | 9.97% |
| 2019 Q3 | -14.29 Million USD | -19.73% |
| 2019 Q2 | -11.94 Million USD | 12.4% |
| 2019 FY | -52.74 Million USD | 32.07% |
| 2018 FY | -77.64 Million USD | -672.96% |
| 2018 Q4 | -14.98 Million USD | 18.73% |
| 2018 Q3 | -18.43 Million USD | 20.69% |
| 2018 Q2 | -23.24 Million USD | -10.75% |
| 2018 Q1 | -20.98 Million USD | -785.13% |
| 2017 Q1 | -3.02 Million USD | -52.72% |
| 2017 FY | -10.04 Million USD | 16.59% |
| 2017 Q4 | -2.37 Million USD | -30.29% |
| 2017 Q3 | -1.81 Million USD | 35.65% |
| 2017 Q2 | -2.82 Million USD | 6.55% |
| 2016 Q2 | -2.51 Million USD | 56.41% |
| 2016 Q4 | -1.98 Million USD | -5.95% |
| 2016 FY | -12.04 Million USD | 71.36% |
| 2016 Q3 | -1.87 Million USD | 25.78% |
| 2016 Q1 | -5.78 Million USD | 37.38% |
| 2015 Q1 | -6.63 Million USD | -103.76% |
| 2015 FY | -42.04 Million USD | -338.42% |
| 2015 Q4 | -9.23 Million USD | 45.63% |
| 2015 Q3 | -16.98 Million USD | -84.58% |
| 2015 Q2 | -9.19 Million USD | -38.58% |
| 2014 Q2 | -1.98 Million USD | 20.21% |
| 2014 Q1 | -2.48 Million USD | 2.08% |
| 2014 FY | -9.59 Million USD | 33.5% |
| 2014 Q4 | -3.25 Million USD | -74.63% |
| 2014 Q3 | -1.86 Million USD | 5.92% |
| 2013 FY | -14.42 Million USD | -151.22% |
| 2013 Q4 | -2.53 Million USD | 0.0% |
| 2012 FY | -5.74 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1236.422% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -253.792% |
| Nascent Biotech, Inc. | -2.22 Million USD | -700.357% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2587.801% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 121.804% |
| Qrons Inc. | -643.67 Thousand USD | -2672.664% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -4481.205% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 67.848% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4195.524% |
| Skye Bioscience, Inc. | -13.67 Million USD | -30.539% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 75.139% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 463.127% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -6718.963% |
| SQZ Biotechnologies Company | -75.82 Million USD | 76.463% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -526.099% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1061.877% |
| Mesoblast Limited | -84.14 Million USD | 78.791% |
| Marizyme, Inc. | -34.08 Million USD | 47.642% |
| Genus plc | 6.4 Million USD | 378.859% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 283.188% |
| Pharming Group N.V. | -4.87 Million USD | -265.751% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -798.424% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1816.189% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -113.737% |
| ContraFect Corporation | -56.88 Million USD | 68.628% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -291.835% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1172.975% |
| IMV Inc. | -38.67 Million USD | 53.85% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -548.784% |
| MultiCell Technologies, Inc. | -722.81 USD | -2469013.598% |
| ONE Bio Corp. | 13.68 Million USD | 230.446% |
| Accustem Sciences Inc. | -3.74 Million USD | -376.375% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 69.746% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3594.557% |
| Q BioMed Inc. | -3.44 Million USD | -417.963% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 604.153% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -579.233% |
| Biomind Labs Inc. | -1 Million USD | -1667.725% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 67.535% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -515.149% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -168.456% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -857.267% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -59485.337% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -12.459% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -823.466% |
| GB Sciences, Inc. | -1.42 Million USD | -1156.381% |
| Alpha Cognition Inc. | -9.7 Million USD | -83.884% |
| HST Global, Inc. | -140.9 Thousand USD | -12565.801% |
| CSL Limited | 3.7 Billion USD | 100.482% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1486.533% |
| Halberd Corporation | -75.05 Thousand USD | -23680.147% |
| Enzolytics Inc. | -2.14 Million USD | -730.557% |
| Agentix Corp. | -1.37 Million USD | -1201.033% |
| Resverlogix Corp. | -12.74 Million USD | -39.987% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -463.304% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 95.801% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1609.483% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -511.315% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1030.018% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -424.144% |
| AVAX Technologies, Inc. | 6.69 Million USD | 366.657% |
| Zenith Capital Corp. | -8.94 Million USD | -99.564% |
| Genscript Biotech Corporation | -415.79 Million USD | 95.708% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -102345.325% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -626.872% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -10305.835% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -790.233% |
| Kadimastem Ltd | -3.04 Million USD | -487.024% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1713.622% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1320.939% |
| BioStem Technologies, Inc. | -7.77 Million USD | -129.426% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -9733.871% |
| LadRx Corporation | -3.82 Million USD | -366.756% |
| Cell Source, Inc. | -4.32 Million USD | -312.614% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2498.006% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2498.006% |
| NovAccess Global Inc. | -2.46 Million USD | -623.5% |
| Affymax, Inc. | -15.04 Million USD | -18.616% |
| Itoco Inc. | -919.14 Thousand USD | -1841.706% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -321.077% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1494.906% |
| Mobile Lads Corp. | -554.55 Thousand USD | -3118.285% |
| CytoDyn Inc. | -18.05 Million USD | 1.168% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -70805.84% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -8009.398% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -3060.31% |
| SYBLEU INC | -149.18 Thousand USD | -11863.4% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -882.591% |
| International Stem Cell Corporation | -663 Thousand USD | -2591.855% |
| Bioxytran, Inc. | -3.82 Million USD | -367.181% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -33803.875% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -87643.363% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 50.789% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1003.028% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2325.408% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -473.674% |
| Neutra Corp. | -229.48 Thousand USD | -7676.945% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -1.756% |
| PureTech Health plc | -146.19 Million USD | 87.793% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 16.956% |
| IXICO plc | -1.43 Million USD | -1141.962% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -88.041% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 85.348% |
| CSL Limited | 3.81 Billion USD | 100.468% |
| Cellectis S.A. | -108.85 Million USD | 83.605% |